-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Docetaxel is the first treatment that can improve the overall survival (OS) of male patients with metastatic castration-resistant prostate cancer (mCRPC)
.
Cabazitaxel is a second-generation taxane drug that can maintain activity in some tumors that are resistant to docetaxel and new hormone therapies
Taxane drugs docetaxel and cabazitaxel can prolong the overall survival of patients with metastatic castration-resistant prostate cancer (mCRPC), and cabazitaxel is only approved for use after docetaxel treatment
.
Recent data show that they have similar efficacy in first-line mCRPC treatment, but their safety status is different
They have similar efficacy in the first-line mCRPC treatment, but the safety status is different.
The preferences of patients with docetaxel and cabazitaxel were evaluated.
Researchers randomly received docetaxel (75 mg/m2, every 3 weeks × 4 cycles) for mCRPC patients who had not undergone chemotherapy at a ratio of 1:1, and then received cabazitaxel (25 mg/m2, every 3 weeks × 4).
Cycle) treatment, or use the reverse order of administration, and stratify according to the previous use of abiraterone or enzalutamide
.
The primary end point was the patient's preference, which was assessed through a dedicated questionnaire after the second yew drug was used
Reasons for patient preference, prostate-specific antigen response, radiological progression-free survival and overall survival
Common factors affecting patient preference
Common factors affecting patient preferenceTo sum up, in the non-chemotherapy male patients treated with two taxanes, a higher proportion of patients prefer cabazitaxel to docetaxel
.
Less fatigue and better quality of life are the two main reasons for patient preference
Among the non-chemotherapy male patients treated with two taxanes, a higher proportion of patients preferred cabazitaxel to docetaxel
Original source:
Original source:Giulia Baciarello, Remy Delva, Gwenaelle Gravis et al.
Leave a message here
